News & Announcements
Fyodor Biotech Relocates to the University of Maryland BioPark
January 13, 2010
Fyodor Biotechnologies Inc. announced that it has completed its relocation into a new, state-of-the-art facility in the BioInnovation Center at the University of Maryland BioPark in Baltimore, Maryland. The new facility includes executive office and laboratory space for research and development activities, including for Fyodor’s urine-based malaria diagnostic assay.
“Fyodor is now able to conduct its own research and development activities, in addition to the considerable effort currently underway at our contract development laboratory,” said Eddy Agbo, DVM, PhD, Chairman and CEO of Fyodor Biotechnologies. Dr. Agbo added that “the advantages offered by the University of Maryland BioPark go beyond the tangible amenities such as access to core facilities. It also provides the opportunity to interact with other organizations at varying stages of development, providing valuable insight and experience.”
Opened in 2008, the BioInnovation Center offers affordable, pre-built wet lab and office suites with flexible lease terms for emerging bioscience companies. Fyodor joins Gliknik, Westat and the University of Maryland Dermatology Associates, PA. With the expected addition of two additional start-ups, the BioInnovation Center will be nearly full with one laboratory suite still available.
“We are excited to welcome Fyodor to the BioPark,” says the BioPark’s executive director Jane M. Shaab. “We will broker collaborative connections with the University’s faculty research experts and have very high expectations for this exciting science and great company.”
About Fyodor Biotechnologies, Inc
Founded in 2008, Fyodor Biotechnologies is focused on the research, development and manufacture of innovative diagnostic and biopharmaceutical products, first targeted to large emerging “frontier” markets in Africa. Fyodor’s first product is a urine malaria test that can be used at home or peripheral health centers to rapidly diagnose clinical malaria in persons with fever. Fyodor’s efforts are also intended to galvanize biotechnology-based socio-economic development locally in sub-Saharan Africa, enhancing the region’s competitiveness in both the regional and global biotech marketplace, revolutionizing healthcare in the region and providing Fyodor with a unique competitive advantage.
According to the World Health Organization’s World Malaria Report 2008, half of the world's population is at risk of malaria, and an estimated 247 million cases lead to nearly 1 million deaths annually, the majority of deaths in children under the age of five. The US Department of Commerce reports that about 18 million US travelers visited countries affected by malaria in 2008. In addition, malaria continues to be a concern to US military deployed to malaria-endemic regions.
The University of Maryland BioPark, located on the academic medical center campus of the University of Maryland, Baltimore, offers sophisticated laboratory and office space for early stage to mature biomedical companies. To date, the BioPark includes 360,000 square feet in twomulti-tenant buildings and one 638-space parking garage. A third multi-tenant building is expected to begin construction in 2010 and the State of Maryland will open its new Forensic Medical Center in the BioPark in July. The project has created 400 jobs and $180 million in capital investment.
For Release: Immediately
Contact: Julie Evans